Carlsmed, Inc. (CARL)

Carlsmed Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	32.27	27.17	13.78
Revenue Growth (YoY)	-	97.16%	-
Cost of Revenue	-	7.12	3.88
Gross Profit	24.02	20.05	9.9
Selling, General & Admin	-	29.87	21.1
Research & Development	-	14.3	7.4
Operating Expenses	-	44.17	28.49
Operating Income	-24.51	-24.12	-18.59
Interest Expense / Income	-0.15	-0.01	0.31
Other Expense / Income	0.18	0.14	-
Pretax Income	-25.72	-24.85	-18.9
Net Income	-24.54	-24.26	-18.9
Preferred Dividends	-1.18	-0.59	-
Net Income Common	-25.72	-24.85	-18.9
Free Cash Flow	-26.58	-25.65	-17.62
Gross Margin	74.44%	73.80%	71.88%
Operating Margin	-75.96%	-88.80%	-134.93%
Profit Margin	-79.69%	-91.47%	-137.16%
Free Cash Flow Margin	-82.36%	-94.41%	-127.85%
EBITDA	-23.37	-23.53	-18.46
EBITDA Margin	-72.42%	-86.61%	-133.94%
Depreciation & Amortization	0.15	0.15	0.14
EBIT	-23.51	-23.67	-18.59
EBIT Margin	-72.87%	-87.15%	-134.93%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).